Strength in Sight

July 14, 2021FDA Grants Alkeus Pharmaceuticals Breakthrough Therapy Designation
for ALK-001 (C20-D3-vitamin A) for the Treatment of Stargardt Disease

Alkeus Pharmaceuticals is a late-stage biopharmaceutical company developing transformative therapies to prevent blindness. Learn More »

ALK-001

ALK-001 (C20-D3-vitamin A) is a chemically-modified form of vitamin A.
Learn More »

Pipeline

Preventing vision loss caused by serious, progressive retinal degenerative diseases.
Learn More »

For Patients

Ongoing clinical trials for patients diagnosed with Stargardt or age-related macular degeneration (AMD).
Learn More »